Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

October 20, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19
Interventions
DRUG

Tocilizumab

Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.

DRUG

Heparin - Therapeutic dosage

Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours

DRUG

Heparin - Prophylactic dosage

Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.

Trial Locations (3)

Unknown

Fundação São Francisco Xavier, Ipatinga

UNIMED Varginha, Varginha

Universidade Federal de Sergipe, Aracaju

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

lead

University of Sao Paulo

OTHER

NCT04600141 - Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection | Biotech Hunter | Biotech Hunter